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Background/aim: Although the cause of immune activation in the pathogenesis of psoriasis is still unclear, miRs are thought to have an
effect on psoriasis. This work aimed to evaluate the role of miRs (miR-4649-3p, miR-6867-5p, miR-4296, miR-210, and miR-1910-3p)
that target the FOXP3 mRNA and IL-17A mRNA in psoriasis.
Materials and methods: Forty-four psoriasis patients and 44 healthy controls were included in the study. Quantitative real-time PCR
(qRT-PCR) was used for the measurement of miRs. Serum IL-17A levels were determined by an enzyme-linked immunosorbent assay
(ELISA) method.
Results: Plasma miR-1910-3p levels were significantly lower in the patient group than the controls (P = 0.000, fc: 0.10). ROC analysis
showed that plasma miR-1910-3p levels could significantly differentiate psoriasis patients from healthy controls [AUC = 0.912 (0.848–
0.975), P = 0.000]. The plasma miR-4649-3p level was significantly higher in the psoriasis group compared to the controls (P = 0.000,
fc: 2.99).
Conclusion: Decreased expression of miR-1910-3p increases the risk of developing psoriasis by approximately 50-fold and was able to
use for the significant differentiation of psoriatic patients from healthy controls.
Key words: Psoriasis, miR-1910-3p, IL-17A, regulatory T-cells

1. Introduction
Psoriasis is a chronic, systemic inflammatory disease that
affects approximately 1%–3% of the population worldwide. Cytokines, such as IL-17, IL-22, IL-12, IL-23, and
tumor necrosis factor alpha (TNF-α) are secreted from
T-helper lymphocytes (Th), especially Th1 and Th17
subtypes, which have many roles in the pathogenesis of
psoriasis [1,2].
Regulatory T (Treg) cells suppress the immune
activation via inhibition of Th1 and Th17 cells under
homeostatic conditions. Disruption of the regulatory
functions of Treg cells may lead to an increase the
expression of IL-17A in psoriasis [3]. Although the
underlying mechanism of Treg cell dysfunction has not
yet been fully clarified yet, microRNAs (miRs) may be
responsible for this situation [4]. miRs, a member of the
noncoding RNA group, which have important regulatory
roles in cell type identification and cell differentiation.
Several studies have implicated miRs in the pathogenesis
of psoriasis in recent years [4,5].

In the current study, it was aimed to evaulate the
plasma levels of miRs, such as miR-4649-3p, miR-68675p, miR-4296, and miR-210 targeting the Treg cells in the
patients with psoriasis and healthy controls. Additionally,
the circulating levels of miR-1910-3p targeting the IL-17A
mRNA as well as serum levels of IL-17A protein were
measured. To the best of our knowledge, there has been no
study examining the plasma levels of miR-4649-3p, miR6867-5p, miR-4296, and miR-1910-3p in the patients with
psoriasis so far.
2. Materials and methods
The study was initiated with the desicion of Süleyman
Demirel University (SDU) Faculty of Medicine Clinical
Research Ethics Committee (Date 04.07.2018, No:118).
Forty-four psoriatic patients and 44 healthy controls over
the age of 18 years, who were diagnosed with psoriasis
clinically and/or histopathologically, were included in
the study. Inclusion criteria included patients who had
not received any systemic treatment for psoriasis for the
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last 3 months, had not received topical treatment for the
last 3 weeks and had no inflammatory disease other than
psoriasis. Healthy subjects without any known disease and
not using any systemic drugs were included in the control
group. Breastfeeding and pregnant women were excluded
from the study.
Systematic data including age, sex, age at disease onset
(early onset: ≤40 years, late onset: > 40 years), disease
duration, family history, presence of arthritis, nail changes,
smoking, and alcohol consumption were obtained from
participants. The severity of the disease was evaluated
by the Psoriasis Area Severity Index (PASI). The disease
was classified as mild with a PASI score of ≤10 and as
moderate-severe with PASI > 10.
2.1. Measurement of serum IL-17A levels
Peripheral venous blood samples were collected from
the study group into appropriate tubes individually and
centrifuged at 2500 rpm for 10 min. The supernatant was
transferred to an Eppendorf tube and stored at –80 °C until
use. The serum IL-17A levels were analyzed using an IL17A human enzyme-linked immunosorbent assay (ELISA)
kit (Elabscience, Wuhan, China) using a microplate reader
(MRC, UT6100, Holon, Israel).
2.2. miR expression and data analysis
Peripheral blood samples taken into EDTA tubes were
centrifuged for 10 min at 2500 rpm within 2 h. The
plasma was separated into Eppendorf tubes and stored
at –80 °C until use. miRs from the plasma samples
were isolated using a Hybrid-RTM miRNA isolation
kit (GeneAll Biotechnology, Korea) according to the
manufacturer’s instructions. Complementary DNA
(cDNA) was synthesized from the isolated miRs using
the HyperScriptTM reverse transcriptase kit (GeneAll
Biotechnology, Korea). Reverse transcription was carried
out using a SimpliAmp thermal cycler (Thermo Fisher
Scientific Inc.,Waltham, MA, USA). Quantitative real-time
polymerase chain reaction (PCR) reactions (qRT-PCR)
were performed using a high-capacity StepOnePlus realtime PCR System (Thermo Fisher Scientific Inc.) according
to the manufacturer’s instructions. All experiments were
performed in triplicate. The expression levels of miRs were
calculated using the 2-∆∆Ct method.
2.3. Primers
Amplification of the U6 gene was used as a housekeeping
control reaction. The forward and reverse primers were
designed on the basis of the criteria stated in quantitative
stem loop RT-PCR for detection of miRs (Chapter 10) by
Erika Varkonyi-Gasic and Roger P. Hellens. The primer
sequences used in the study are shown in Table 1.
3. Statistical analysis
SPSS statistical software (PASW Statistics for Windows,
Version 20.0, SPSS Inc. IBM Corp., Chicago, IL, USA) was

Table 1. Primary sequences used in the study.
miR

Primary squence

Hsa-miR-4649-3p R: CGAGGAAGAAGACGGAAGAAT
F: TCTGAGGCCTGCCTCTCCCCA
Hsa-miR-6867-5p R: CGAGGAAGAAGACGGAAGAAT
F: TGTGTGTGTAGAGGAAGAAGGGA
Hsa-miR-4296

R: CGAGGAAGAAGACGGAAGAAT
F: ATGTGGGCTCAGGCTCA

Hsa-miR-210

R: CGAGGAAGAAGACGGAAGAAT
F: AGCCCCTGCCCACCGCACACTG

Hsa-miR-1910-3p R: CGAGGAAGAAGACGGAAGAAT
F: GAGGCAGAAGCAGGATGACA
U6 snRNA

R: CGCTTCACGAATTTGCGTGTCAT
F: GCTTCGGCAGCACATATACTAAAAT

used to evaluate all statistical analyses. Continuous variables
were expressed as mean ± SD and the level of significance
was assigned as P < 0.05. Normality distributions of the
samples was tested with the Kolmogorov–Smirnov test.
ANOVA followed by post hoc tests were used to evaluate
the group means. Independent sample t-test and Mann–
Whitney U test were used for normally distributed
variables and nonnormally distributed variables,
respectively. Differences in the expression of miRNAs were
calculated as fold changes using the 2-ΔΔCt equation. Each
sample was run in triplicate for analysis. The expression
levels of miRNAs were normalized to RNU6 (U6 small
nuclear RNA). The ΔCt was calculated by subtracting
the Ct values of RNU6 from the Ct values of the miRNA
of interest. Receiver operating characteristic (ROC)
curves were plotted to determine the strength of miRs
in the classification of patient groups. Logistic regression
analysis was used to determine the risk of developing the
independent variables. ΔCT values of miRNAs were used
for logistic regression analysis. Pearson correlation analysis
was used to determine the association between between
independent variables. Z-test was used to compare two
independent proportions of categorical variables.
Achieved power of the study was found to be 95% for
results the area under the ROC curve (AUC) under the
null hypothesis of 0.9120 using a two-sided significance
level of 0.050.
4. Results
The characteristics of the patient and control groups
included in the study are given in Table 2. A comparison
of the age at disease onset, PASI score, nail involvement,
psoriatic arthritis, family history, and smoking habits of
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Table 2. Clinical and demographic characteristics, MiRNA ΔCT
and IL-17A levels in patient and control groups.

Male/female, n
Age, mean±SD
Age onset of the
disease, mean ± SD
PASI, mean ± SD
Female
Male
Early onset
Late onset
Duration of the
disease,
year, mean ± SD
miR-1910-3p ΔCT,
mean ± SD
miR-4649-3p ΔCT,
mean ± SD
miR-4296 ΔCT,
mean±SD
miR-210 ΔCT, mean
± SD
miR-6867-5p ΔCT
mean ± SD
IL-17A, mean ± SD

Patients
(n: 44)
28/16
43.02 ±
16.26
31.36 ±
18.81
9.27±6.08

Controls
(n: 44)
28/16
42.82 ±
16,14

6.23 ± 3.62
11.01 ±
6.56
10.32 ±
6.60
6.76 ± 3.76

-

-

-

P

FC***

1

-

0.953* -

-

0.003**

-

0.03**

11.65 ±
9.18

-

-

14.54 ±
2.39

17.80 ± 0.87 0.000

0.10

16.1 ± 1.97 14.63 ± 1.82 0.000

2.99

8.72 ± 2.25 9.17 ± 1.30

0.255

0.73

18.94 ± 1.02 0.555

1.13

15.54 ± 1.08 0.354

1.23

42.28 ±
25.51

-

19.12 ±
1.69
15.84 ±
1.80
167.03 ±
374.23

0.033

-

*P: Independent samples t test between groups (patients and
controls), **P: Independent samples t test between subgrops
(psoriasis), ***FC: Fold change.

the patients with psoriasis is given in Table 3. The mean
PASI score in male patients (11.01 ± 6.56) was significantly
higher than the mean PASI score in female patients (6.23
± 3.62) (P = 0.003). The ratio of mild (PASI < 10) psoriasis
patients (63.6%) was significantly higher than the ratio
of moderate-severe (PASI ≥ 10) patients (16, 36.4%) (P
= 0.008). The number of patients with moderate-severe
plaque psoriasis (PASI ≥10) was significantly higher in
males than in females (P = 0.013). The mean PASI score
(10.32 ± 6.60) of patients belonging to the early onset
group was significantly higher than the mean PASI score
of the patients who were classified as the late onset group
(6.76 ± 3.76) (P = 0.030).
The mean plasma miR-1910-3p level was significantly
lower in the patient group (14.54 ± 2.39) compared to
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the control group (17.80 ± 0.87) (P = 0.000, fc: 0.10). The
mean plasma miR-4649-3p level was significantly higher
in the patient group (16.21 ± 1.97) than the control group
(14.63 ± 1.82) (P = 0.000, fc: 2.99). The mean plasma miR4296 level was lower in the patient group (8.72 ± 2.25)
compared to the control group (9.17 ± 1.30); however,
this difference was not statistically significant (P = 0.255,
fc: 0.73). There was no statistically significant difference
in the mean plasma levels of miR-210 and miR-6867-5p
between the patient and control groups. The mean serum
IL-17A levels were significantly higher in the patient group
(167.03 ± 374.23 ng/L) than in the control group (42.28
± 25.51 ng/L) (P = 0.033). A comparison of the plasma
miRNAs and IL-17A levels and miRNA fold change levels
between the patient and control groups are given in Table
2 and Figure 1, respectively. IL-17A levels significantly
differs with the age at disease onset. Serum IL-17A levels
were significantly higher in patients with early age at onset
of disease (223.78 ± 435.21 ng/L) compared to those with
late age at disease onset (31.69 ± 12.14 ng/L) (P = 0.020).
In logistic regression analyses, it was found that males
had an approximately 20-fold higher likelihood to develop
the disease (OR = 20.742, P = 0.092). A decrease in plasma
miR-1910-3p level was found to increase the likelihood of
having the disease by approximately 50-fold (OR = 50.801,
P = 0.009) (Table 4).
In correlation analysis, a statistically significant
negative correlation was found between serum IL-17A and
miR-6867-5p expression levels (r: –0.314, P = 0.015). There
was also a statistically significant correlation between age
at disease onset and the expression level of plasma miR4649-3p (r: 0.327, P = 0.03). Moreover, a statistically
significant negative correlation was shown between IL17A levels and PASI (r: 0.373, P = 0,013) and age at disease
onset (r: –0.382, P = 0.010) (Table 5).
In Receiver Operating Characteristic Curve (ROC)
analysis, the plasma miR-1910-3p level was found to be
significantly better at discriminating psoriasis patients
from healthy controls (AUC = 0.912 (0.848 - 0.975), p =
0.000) (Table 6, Figure 2). The cut-off value of plasma miR1910-3p level was 17.1114 (Sensitivity = 0.864, Specificity
= 0.818). The sensitivity of a test is its ability to identify the
patient as a patient; whereas specificity can be defined as
the power to identify healthy people as healthy in general.
The cut-off value of the other parameters studied was not
determined, since the predictive power of the disease was
below 50%.
5. Discussion
IL-17A, a member of the IL-17 family of cytokines, plays
an important role in the pathogenesis of psoriasis by
increasing the production of proinflammatory cytokines
[6]. A significant increase in serum and tissue levels of IL-
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Table 3. Clinical findings of psoriatic patients.
Clinical findings
Age at disease onset
PASI
Nail involvement
Psoriatic arthritis
Family history
Smoking

n (%)

P*

Early onset (Type 1 < 40 year)

31 (70.5%)

0.000

Late onset (Type 2 ≥ 40 year)

13 (29.5%)

Mild (PASI <10)

28 (63.6%)

Moderat-severe (PASI ≥10)

16 (36.4%)

Yes

12 (27.3%)

No

32 (72.7%)

Yes

2 (4.5%)

No

42 (95.4%)

Yes

13 (29.5%)

No

31 (70.5%)

Yes

18 (40.9%)

No

26 (59.1%)

0.008
0.000
0.000
0.000
0.083

* Z test for two independent variables.

miRNA expression (fold change)

Relative expression levels of miRNAs
3.5
3
2.5
2
1.5
1
0.5
0
miR-210

miR-1910
Psoriasis

miR-4269

miR-4649

miR-6867

Control

Figure 1. Comparison of miRNA fold change levels in patients with psoriasis and
control group.
17A in patients with psoriasis has been reported [3,6,7].
In the current study, the serum IL-17A level (167.03 ±
374.23 ng/L) was significantly higher in psoriatic patients
compared to the healthy controls (42.28 ± 25.51 ng/L) (P =
0.033). Although it was reported that IL-17 levels increase
with increasing disease severity [8–11], there are not
enough studies examining the relationship between serum
IL-17A levels and the severity of psoriasis. In a recent
study, it has been reported that IL-17A levels in the skin
and serum increase as PASI increases; moreover, serum

IL-17A levels were observed to be significantly higher in
the patient group with active psoriasis which have new
lesion development in the last month compared to patients
with stable disease [7]. In the current study, the severity
of psoriasis was significantly correlated with the increase
in serum IL-17A levels (r: 0.373, P = 0.013). Therefore,
it can be suggested that serum IL-17A levels increase as
the severity of the disease increases, alternately, enhanced
serum IL-17A levels may increase inflammation and
disease severity. Our results suggest that serum IL-17A
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Table 4. Examination of age, sex, miRNA and IL-17A levels by logistic regression analysis.
Clinical and laboratory properties

OR

Age

95% Confidence interval

P*

Lower value

Upper value

1.000

0.917

1.090

0.998

Sex

20.742

0.607

709.057

0.092

miR-1910-3p ΔCT

50.801

2.701

955.604

0.009

miR-4649-3p ΔCT

0.355

0.097

1.290

0.116

miR-4296 ΔCT

0.416

0.098

1.759

0.233

miR-210 ΔCT

2.543

0.088

73.395

0.586

miR-6867-5p ΔCT

0.108

0.009

1.264

0.076

IL-17A

1.009

0.999

1.019

0.095

* Logistic regression analysis.

Table 5. Correlations between plasma miRNA levels, IL-17A,
disease onset age, disease duration, disease severity (PASI).
Disease onset age PASI

IL17-A

miR-1910-3p

.100

.032

0.101

miR-4649-3p

.327*

.127

0.092

miR-4296

–.214

–.033

0.076

miR-6867-5p

–.208

.064

–.314*

IL-17A

–.382**

.373**

1

*P < 0.05, ** P < 0.01, ***P < 0.001.
Table 6. Evaluation of plasma miRNA and serum IL-17A levels
by ROC curve analysis.
AUC*

P*

miR-1910-3p ΔCT

0.912

0.000

miR-4649-3p ΔCT

0.255

0.000

miR-4296 ΔCT

0.515

0.809

miR-210 ΔCT

0.416

0.176

miR-6867-5p ΔCT

0.398

0.098

IL-17A

0.394

0.087

* Area under the curve (AUC).

level can be used as an objective parameter to determine
the severity of psoriasis.
In our study, serum IL-17A levels were significantly
higher in patients with early onset psoriasis (223.78 ±
435.21 ng/mL) than those with late onset group (31.69 ±
12.14 ng/mL), respectively (P = 0.020). In addition, serum
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IL-17A levels were observed to be increased significantly
as the age at disease onset decreased (r: –0.382 P = 0.005).
To the best of our knowledge, there has been no study that
show a correlation between serum IL-17A levels and age
at disease onset. As the disease progresses more severely
in the patients with early-onset disease, it is likely that
the mean serum IL-17A levels are likely higher in these
patients.
miRs usually bind to the 3’UTR region on the target
mRNA, causing either the degradation of the mRNA
sequence or an inhibition of its translation [5]. Previous
studies have evaluated the levels of miR-1266, miR-340
and miR-197, which are thought to act via IL-17A in
patients with psoriasis [12–15]. In two studies, miR1266
were found to be significantly higher in plaque psoriasis
patients than in healthy controls and showed a correlation
with PASI, suggested that the effect of miR-1266 on the
pathogenesis of psoriasis was not through a regulation of
IL-17A expression but through a more upstream signaling
mechanism or miR-1266 is not likely to regulate IL-17A
expression directly but may be involved in the pathogenesis
of psoriasis by regulating other target molecules [12–13].
Bian et al. have shown that miR-340 can bind specifically
to the 3’UTR region of IL-17A and reduce endogenous
IL-17A expression in mouse skin with psoriasis [14].
Elharrar et al. reported that miR-197 expression was lower
in psoriatic skin keratinocytes than in the healthy skin,
suggesting that a decrease in the suppression of the IL17A pathway may lead to an accelerated proinflammatory
process [15]. In our study, plasma levels of miR-1910-3p
(targets IL-17A mRNA) were found to be significantly
lower in the patient group compared to the controls (P
= 0.000, fc: 0.10). Additionally, we found that a decrease
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Figure 2. Evaluation of plasma miRNA and serum IL-17A levels by ROC curve
analysis.
in plasma miR-1910-3p levels could predict nearly a 50fold increase in the risk of developing the disease (OR
= 50.801, P = 0.009). It may be suggested that decreased
levels of miR-1910-3p may lead to the loss of suppression
of the IL-17A mRNA and a concomitant increase in the
expression of IL-17A protein. This may then accelerate
the production of proinflammatory molecules involved
in the pathogenesis of psoriasis and lead to enhanced
keratinocyte proliferation.
Currently, there are no laboratory-based methods
for the diagnosis of psoriasis. A ROC curve analysis is
used to determine the power of a particular parameter
to distinguish patients from healthy individuals. Our
ROC curve analysis indicated that plasma miR-19103p levels could be used to distinguish psoriasis patients
from healthy controls [AUC = 0.912 (0.848–0.975), P =
0.000]. Furthermore, the ROC curve analysis revealed
that the plasma miR-1910-3p levels showed a stronger
discriminatory power to distinguish psoriasis patients
from controls when compared to previously studied miRs
[16–18]. We strongly think that plasma miR-1910-3p
levels can be used as a diagnostic biomarker for psoriasis.
Impaired Treg cell function has been suggested as one
of the causes of T cell activation in psoriasis. Although
the mechanisms for the decline in suppressive functions
of Treg cells are still unclear, miRs are thought to play a
role [4,19]. miR-4649-3p, is thought to be effective on

Treg cells. Although miR-4649-3p has been implicated in
different diseases, it has not been studied in the context
of psoriasis [20,21]. miR-4649-3p was suggested to inhibit
cell proliferation in nasopharyngeal carcinoma by targeting
protein tyrosine phosphatase SHP-1 [20]. Additionally,
miR-4649-3p was suggested to be a biomarker that can
predict the transition to chronic disease in patients with
brucellosis [21]. In the current study, the plasma miR4649-3p level was significantly higher in psoriatic patients
compared to the control group (P = 0.000, fc: 2.99).
Increased expression of miR-4649-3p in psoriasis may
lead to a decrease in Treg cell production (by suppressing
FOXP3 gene) causing an exacerbation of immune
response. We also found that miR-4649-3p plasma levels
decreased significantly as the age at disease onset decreased
(r: 0.323, P = 0.03), suggesting that Treg cell development
and function are likely to also be regulated by proteins and
miRs other than miR-4649-3p in the early onset psoriasis
group.
To the best of our knowledge, there are no studies
examining the role of miR-4296 in different disease states
including psoriasis. In the current study, plasma levels
of miR-4296 were lower in the patient group compared
to controls, but the difference did not reach statistical
significance (P = 0.255, fc: 0.73). In fact, that miR-4296 was
expected to show high expression in the patient group as
the miRNA was predicted to target the mRNA of FOXP3
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with a high target score MicroRNA target prediction
database (miRDB). This suggests that the role of miR-4296
in the pathogenesis of psoriasis may be via other relevant
target genes rather than directly through the inhibition
of FOXP3. In addition, the fact that the patient cohort in
the current study had predominantly mild disease and
belonged to a different population from previous studies
could also have led to distinct outcomes.
Studies have evaluated the expression of miR-210
in psoriatic patients and higher miR210 levels were
detected [4,22]. In these studies, it was reported that miR210 regulated Treg cell functions by targeting FOXP3
in psoriasis and increased levels of miR-210 in psoriasis
could skew T cells differentiation to Th17 and Th1, but
not to Th2 [4,22]. In contrast, Abdul-Maksoud et al. found
significantly lower miR-210 levels in another inflammatory
disease RA, and negatively correlated miR-210 levels with
clinical and laboratory inflammatory markers [23]. In our
study, there was no significant difference in the plasma
miR-210 levels between the patient and control groups (P
= 0.555, fc: 1.13) suggesting that the association of a single
miRNA with the risk of developing a disease can vary
significantly between different populations.
In the present study, no significant difference was
found in the plasma levels of miR-6867-5p between the
patient and control groups (P = 0.354, fc: 1.23). To the best
of our knowledge, miR-6867-5p expression has not been
evaluated in patients with psoriasis but has been studied in
the context of endometriosis, suggesting regulatory effect
of miR-6867-5p on cell proliferation [24]. In our study,
there was a significant negative association between the
plasma level of miR-6867-5p and serum level of IL-17A
(r: -0.315 p = 0.038). The lack of a significant difference in
the plasma levels of miR-6867-5p between the patient and
control groups together with the presence of a significant
negative association between miR-6867-5p and IL-17A in
the patient group suggests that miR-6867-5p may directly
regulate the IL-17A mRNA rather than the activity of Treg
cells in patients with psoriasis.

The severity of the disease was not homogeneously
distributed in the patient cohort as the number of patients
with mild psoriasis was higher than the number of patients
with moderate-severe psoriasis is the limitation of the
study. On the other hand, evaluation of circulating levels
of miR-1910-3p (predicted to target the IL-17A mRNA)
and miR-4649-3p, miR-4296, miR-6867-5p (predicted to
target the FOXP3 mRNA that regulates the functions of
Treg cells), which had not been studied in patients with
psoriasis before, are the strengths of the current study.
Our results show that decreased plasma levels of
miR-1910-3p and increased levels of miR-4649-3p may
be associated with psoriasis. Particularly, decreased miR1910-3p levels increase the risk of developing psoriasis by
approximately 50-fold, and plasma levels of miR-1910-3p
were able to significantly differentiate psoriatic patients
from healthy controls. Therefore, plasma levels of miR1910-3p could be used as a biomarker for the diagnosis
of psoriasis. Also miR-1910-3p and miR-4649-3p, could
be useful targets for the development of drugs used in the
treatment of psoriasis. Further and comprehensive studies
that show relevant tissue expressions of miRs in addition to
the plasma levels are needed in order to better determine
the roles of miRs on cytokines and signaling pathways in
the pathogenesis of psoriasis and to use them as target
molecules for therapeutic purposes.
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